GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer

Abstract GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy for high-risk early breast cancer. This study reports the secondary endpoints pathological complete response (pCR) and overall survival (OS). Patients (n = 2887) were randomized 1:1 between idd epirubicin, nab-paclitaxel,...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, Peter Klare, Knut Engels, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marmé, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Sabine Seiler, Christine Solbach, Sabine Schmatloch, Julia Rey, Sibylle Loibl
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2024-07-01
Serie:	npj Breast Cancer
Accesso online:	https://doi.org/10.1038/s41523-024-00675-x
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!